ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,555.74
-0.16%
US Tech 100
19,020.40
-1.06%
Dow Jones
40,358.09
-0.14%
Brent Oil
80.74
-0.04%
Bitcoin
66,243.52
0.49%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Cellectis Nom Eo 05 (ALCLS) Quote

Cellectis Nom Eo 05

Cellectis Nom Eo 05 (ALCLS)

EU
1.826
0.004
( 0.22% )
Updated: 04:12:44
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
1.826
Bid
1.802
Ask
1.814
Volume
1,522
1.812 Day's Range 1.838
0.888 52 Week Range 3.44
Market Cap
83.768M
Previous Close
1.822
Open
1.828
Last Trade
56
@
1.826
Last Trade Time
04:00:39
Financial Volume
-
VWAP
-
Average Volume (3m)
103,103
Shares Outstanding
45,874,895
Dividend Yield
-
PE Ratio
-0.84
Earnings Per Share (EPS)
-2.2
Revenue
9.24M
Net Profit
-101.06M

About Cellectis Nom Eo 05

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.cellectis.com
Headquarters
Paris, Paris, Fra
Founded
1970
Cellectis Nom Eo 05 is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ALCLS. The last closing price for Cellectis Nom Eo 05 was 1.82 €. Over the last year, Cellectis Nom Eo 05 shares have traded in a share price range of 0.888 € to 3.44 €.

Cellectis Nom Eo 05 currently has 45,874,895 shares outstanding. The market capitalization of Cellectis Nom Eo 05 is 83.58 € million. Cellectis Nom Eo 05 has a price to earnings ratio (PE ratio) of -0.84.

ALCLS Latest News

More News

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, July 05, 2024 (GLOBE NEWSWIRE...

July 05 2024
GlobeNewswire Inc.

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS...

July 05 2024
GlobeNewswire Inc.

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage...

June 28 2024
GlobeNewswire Inc.

Résultats de l’Assemblée Générale Mixte de Cellectis du 28 juin 2024

Résultats de l’Assemblée Générale Mixte de Cellectis du 28 juin 2024 NEW YORK, 28 juin 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de...

June 28 2024
GlobeNewswire Inc.

Cellectis publie un article scientifique dévoilant trois facteurs clés pour une édition efficace avec des TALE base editors

Cellectis publie un article scientifique dévoilant trois facteurs clés pour une édition efficace avec des TALE base editors NEW YORK, 20 juin 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext...

June 20 2024
GlobeNewswire Inc.

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth:...

June 12 2024
GlobeNewswire Inc.

Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications

Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications NEW YORK, 12 juin 2024 (GLOBE NEWSWIRE) --  Cellectis (Euronext...

June 12 2024
GlobeNewswire Inc.

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, June 05, 2024 (GLOBE NEWSWIRE...

June 05 2024
GlobeNewswire Inc.

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS...

June 05 2024
GlobeNewswire Inc.

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis...

June 04 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.068-3.590285110881.8941.9481.788369741.86510014DE
40.1186.908665105391.7081.9481.634597311.76505105DE
12-0.694-27.53968253972.523.0251.6341031032.28870381DE
26-0.774-29.76923076922.63.0251.634936382.39324941DE
52-0.652-26.31154156582.4783.440.8881788692.46067464DE
156-10.054-84.629629629611.8813.220.8881687263.45933643DE
260-11.394-86.187594553713.2228.450.8881421446.7970314DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUZENuZee Inc
$ 2.03
(97.09%)
596.27k
ALLRAllarity Therapeutics Inc
$ 0.2997
(80.00%)
6.85M
RGCRegencell Bioscience Holdings Ltd
$ 23.00
(53.74%)
62.72k
NIVFNewGenIvf Group Ltd
$ 1.09
(25.16%)
466.15k
KITTNauticus Robotics Inc
$ 3.96
(21.10%)
48.34k
CONNConns Inc
$ 0.261
(-48.52%)
38.32k
VSTMVerastem Inc
$ 2.80
(-22.01%)
1.53k
ATPCAgape ATP Corporation
$ 0.1704
(-20.74%)
43.53k
ALPPAlpine 4 Holdings Inc
$ 0.4899
(-18.34%)
15.57k
SLRXSalarius Pharmaceuticals Inc
$ 2.16
(-17.24%)
4.6k
ALLRAllarity Therapeutics Inc
$ 0.2997
(80.00%)
6.85M
SLNASelina Hospitality PLC
$ 0.0276
(6.15%)
2.44M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 11.57
(-15.55%)
703.91k
NUZENuZee Inc
$ 2.03
(97.09%)
597.16k
NIVFNewGenIvf Group Ltd
$ 1.09
(25.16%)
466.15k

Discussion

View Full Feed
Margin Buu Margin Buu 8 minutes ago
One of the biggest FUD tactics has been around the timeframe of this approval. There have been 1000 posts by nefarious actors just trying to convince us that the 150-day review pathway (requested by the company) was in business days when the review clock has always been CALENDAR DAYS. Not only is t
NWBO
chicks0123 chicks0123 11 minutes ago
Good morning CLNVERS
CLNV
urge2surge urge2surge 12 minutes ago
Copied and posted word for word.
FDCT
dirkv dirkv 13 minutes ago
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.278
52w: 0.278 – 2.4
https://www.thera.vet/en/home

https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf

their products:
https://bioc
dirkv dirkv 14 minutes ago
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.278
52w: 0.278 – 2.4
https://www.thera.vet/en/home

https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf

their products:
https://bioc
manfromjax manfromjax 16 minutes ago
WOW, am I going to be happy that I picked up 2000 more shares of ALLR at .17!!!
average is now .32.
Was up to .30 as I sit here in Riga Latvia.
ALLR
ShadowDiviner72 ShadowDiviner72 17 minutes ago
Shorts can say whatever they want, but why is the cost to borrow fee decreasing rapidly?

In 10 trading days from 96% to 9%

Apparently the demand for short shares is decreasing quickly
MAXN
MrLWLG101 MrLWLG101 19 minutes ago
The news about the appointment of Yves LeMaitre, a renowned and respected figure in the industry and business, acts as a magnet for short-sellers. I see this more in terms of "defamation and slander" against him and the entire BOD of LWLG, without thorough reasons and evidence. The moderators should
LWLG
SkeBallLarry SkeBallLarry 20 minutes ago
Graceland (from The Concert in Hyde Park >

https://youtu.be/0VTcBO4q5kY
SkeBallLarry SkeBallLarry 20 minutes ago
Graceland (from The Concert in Hyde Park >

https://youtu.be/0VTcBO4q5kY
SkeBallLarry SkeBallLarry 21 minutes ago
BreakTime ~ Graceland (from The Concert in Hyde Park >

https://youtu.be/0VTcBO4q5kY
palaypu0406 palaypu0406 22 minutes ago
whenever large wires that too international wires transfer in, or anytime if there is a larger inward (even domestic) with regular balances not anywhere near to the size of the funds coming in, bank does keep the funds on hold and release within the defined date.
ITUP
1hunglo 1hunglo 23 minutes ago
AGREED.
RDGL
palaypu0406 palaypu0406 25 minutes ago
Dear Snow and all (I am addressing Snow first as he is the eldest among the group),
I am very happy to share that we have money availability on the 7/29/2024) -- This is one year of burn -- facing so many challenges, insults, humiliation and spits on face. Despite that - we never let our spi
ITUP
Margin Buu Margin Buu 30 minutes ago
Thanks for pointing out Leg-ends hypocrisy. He’s a spreader of FUD and not very good at it.
NWBO
Jack Torrance Jack Torrance 32 minutes ago
I personally think 80%.
MNMD
CaptainObvious CaptainObvious 37 minutes ago
"The reality about this stock is nobody knows anything....

...something I will bet a lot on is that the stock will not get above $1"
NWBO
Capt_Smith77 Capt_Smith77 60 minutes ago
I'll believe in their backing of G42 when it doesn't amount to diluting shareholders, and there's an actual appreciation in the stock price. To date, the company's financing has done nothing but reduce shareholder value.

Now on a more positive note, at least we haven't seen any recen
VRSSF
tedgoeseast tedgoeseast 1 hour ago
Everyone else has already seen this on the news today it's nothing new
Sonar Sonar 1 hour ago
The only document related to Mr Norward and Oceanwide Plaza:
https://www.myvisajobs.com/Visa-Sponsor/Tohigh-Construction-Investment/1236463.htm
Relationship between Mr Norward and ESSGCorp.net
https://investorshub.advfn.com/uimage/uploads/2024/7/24/wzxfcScreenshot_2024-07-24_094
JBZY
Capt_Smith77 Capt_Smith77 1 hour ago
Of course they're not still testing the software. At least not anyone but maybe Blue Yonder, which was the last one to join the Beta program, IIRC.

Still, the company has advertised them all as partnerships, which they are not. They've even reworded how things are said in recent PRs
VRSSF

Your Recent History

EU
ALCLS
Cellectis Nom Eo 05
NASDAQ
CHRD
Chord Energy
LSE
BLEY
C.H. Bailey
COIN
SKBEUR
Sakura Bloom
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved